Fungemia due to rare yeasts constitutes an emerging but poorly investigated condition. Data on risk factors, clinical features, therapy, and outcome of episodes of fungemia due to rare (non-Candida, non-Cryptococcus) yeasts were analyzed in a population-based surveillance program conducted in 29 Spanish hospitals between May 2010 and April 2011. Species identification (DNA sequencing) and antifungal susceptibility testing (EU-CAST and CLSI methods) were centrally performed. Fourteen out of 767 episodes of fungemia (1.8%) were due to rare yeasts: Trichosporon asahii, Magnusiomyces capitatus (three cases each), Rhodotorula mucilaginosa, Wickerhamomyces anomalus (two cases each), and Pichia kudriavzevii, Cyberlindnera fabianii, Kodamaea ohmeri, and Lodderomyces elongisporus (one case each). Misidentification by local laboratories was observed in two isolates. Breakthrough fungemia occurred in two episodes due to M. capitatus. MIC values for echinocandins were generally high (particularly for M. capitatus, T. asahii, and R. mucilaginosa isolates [≥2 mg/l]), whereas T. asahii isolates showed MICs ≥1 mg/l to amphotericin B. Patients with fungemia due to rare yeasts were more likely to have hematological malignancies (28.6% vs. 7.8%; P-value = .021), chronic lung disease (50.0% vs. 22.3%; P-value = .023), and prior immunosuppression (57. 
Introduction
The last years have witnessed an increase in the incidence of candidemia, which now ranks as the fourth most common cause of bloodstream infection (BSI). The widespread use of central venous catheters (CVC), parenteral nutrition, and broad-spectrum antibiotics has contributed to this epidemiological change, as well as the increasing number of subjects receiving immunosuppressive therapy. 1 This trend has been mirrored by the emergence of yeast infections due to agents not belonging to the genera Candida or Cryptococcus. 2 These rare yeasts accounted for 0.7% of fungemia episodes over an 8-year period in a nationwide surveillance in Denmark. 3 The corresponding figure in a populationbased study in the Paris metropolitan area was 1.3% 4 , whereas the frequency reported from a tertiary-care cancer center was expectedly higher (2.8%) due to the role of neutropenia as predisposing factor. 5 In addition to the potential risk of misidentification by conventional phenotypic methods, 6, 7 the clinical management of BSI due to rare opportunistic yeasts involves other challenges, such as the intrinsic resistance to certain classes of antifungal agents, the absence of well-established clinical breakpoints (CBPs) for interpreting the results of antifungal susceptibility testing, and the particular susceptibility faced by severely immunocompromised hosts. 8 Thus, and despite the relatively low intrinsic virulence of some of these yeasts, the mortality rate in previous studies ranged from 34% to 76%. 5, [9] [10] [11] The increasing relevance of these rare yeasts has recently led to the drawing up of specific guidelines by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Fungal Infection Study Group (EFISG), and the European Confederation of Medical Mycology (ECMM). 4 Unfortunately, most of our current knowledge about the risk factors, optimal therapy, and determinants of outcome in this form of invasive fungal disease is based on single case reports, 12, 13 small series, 7, 14, 15 or retrospective experiences. 5, 10, 11 Moreover, some of the previous studies have been centered on specific pathogens 6, 9, 11, [16] [17] [18] [19] or patient groups. 5, 11 With these drawbacks in mind, we aimed at assessing the incidence, clinical and microbiological features and outcome of patients with BSI due to rare (non-Candida, non-Cryptococcus) yeasts by means of the analysis of a population-based surveillance recently conducted in Spain.
Materials and methods

Study setting and design
The CANDIPOP Project (ClinicalTrials.gov number: NCT01236261) was a prospective population-based surveillance program on both Candida and non-Candida yeasts causing BSI performed between May 2010 and April 2011 in 29 center from five cities in Spain (Barcelona, Bilbao, Madrid, Seville, and Valencia), which served about 20% of the Spanish population by that time. The methodology of the CANDIPOP Project has been detailed elsewhere. [20] [21] [22] The study protocol was approved by the local ethics committees, and written informed consent was obtained at enrollment. In the present substudy we compared the predisposing conditions, clinical presentation, therapy, and outcome of episodes of BSI due to uncommon yeasts ("rare yeasts BSI group") with those due to Candida species ("Candida BSI group"). We used a pragmatic definition for "rare opportunistic yeasts" that was based on taxonomic rather than statistical considerations: every yeast pathogen different from Candida spp. or Cryptococcus spp. were recovered (either in its anamorphic or teleomorphic states) from blood cultures. 5 The primary outcome was clinical failure, defined as: (1) all-cause mortality within the first 30 days from the first positive blood culture and/or (2) persistent fungemia for ≥72 hours after the initiation of antifungal therapy. As secondary outcomes we separately analyzed early (0-7 days), late (8-30 day), and overall (0-30 day) all-cause mortality. 22 
Study definitions
An incident episode was defined as the first blood culture yielding a yeast-like fungus throughout the study period (index blood culture). In the absence of specific diagnostic criteria, 23 we defined BSI due to rare opportunistic yeasts by the demonstration of a non-Candida and non-Cryptococcus yeast in the index culture in the context of a clinical picture compatible with fungemia that eventually prompted the initiation of systemic antifungal therapy. The isolation of the same species in a given patient >30 days after the index culture was considered as a distinct episode, as well as the subsequent isolation at any time of a second different species. Different sources of BSI (catheter-related, abdominal or primary) were categorized as previously described. 20, 22, 24 Breakthrough BSI was defined by the occurrence of fungemia in a patient receiving systemic antifungal therapy for any reason for at least 72 hours before the date of the index culture. Exposure to systemic antifungal agents was recorded within the preceding month. Early CVC removal was defined by the removal of the line within the first 48 hours from the incident BSI (removal within this timeframe of all CVCs in patients with multiple vascular accesses was required). Initial antifungal therapy was that provided within the first 72 hours.
Species identification and antifungal susceptibility testing
Yeast isolates were initially processed at each participating center by local routine methods. All the strains were subsequently forwarded to the Mycology Reference Laboratory at the Spanish National Center for Microbiology (Majadahonda, Madrid) for species confirmation and antifungal susceptibility testing. A PCR-based identification was done by sequencing the internal transcribed spacer 1 (ITS1) and ITS2 regions from the ribosomal DNA with fungusspecific primers. 25 The names used were based on the most 
Statistical analysis
Quantitative data were shown as the mean ± standard deviation (SD) or the median with interquartile ranges (IQRs). 
Results
Incidence rates
We identified 788 episodes of yeast fungemia during the surveillance period. Twenty-one case-patients did not consent to participate in the study. Out of the remaining 767 episodes, Cryptococcus spp. was isolated in 5 (0.6%) and rare opportunistic yeasts in 14 (1.8%). Thus, we analyzed 14 and 748 episodes within the rare yeasts BSI and Candida BSI groups, respectively. The most common species within the former group were: C. albicans (45.1%), C. parapsilosis complex (25.5%), C. glabrata (12.8%), C. tropicalis (7.4%), C. guilliermondii (1.7%), and C. lusitaniae (1.2%).
The crude annual incidence rates for BSI due to rare yeasts (non-Candida, non-Cryptococcus) over the surveillance period were 0.14 cases per 100,000 population, 0.016 per 1,000 hospital admissions, and 0.02 per 10,000 patientsdays. In comparison, the corresponding overall crude incidence for yeast fungemia during the same period was 8.3 cases per 100,000 population. The microbiological identification is detailed in Table 1 . Discrepancies between the local identification and that provided by the sequencing of the ITS regions were observed in two isolates (14.3%): one Cyberlindnera fabianii isolate had been misidentified as C. utilis and one Wickerhamomyces anomalus isolate had been misidentified as C. albicans. Details on the predisposing conditions, clinical and microbiological features, therapy, and outcomes of the 14 episodes of BSI due to rare yeasts are provided in Table 2 . A bacterial pathogen was concurrently isolated in one of them (Enterococcus faecium [case 13]).
Antifungal susceptibility
The results of antifungal susceptibility testing according to the EUCAST and CLSI procedures are shown in Table 3 . Overall, EUCAST tended to provide higher MICs than CLSI. Regardless of the method used, MIC values among Pichia isolates were generally low for all tested agents (≤0.12 mg/l) with the sole exception of fluconazole. On the other hand, echinocandins generally exhibited high MICs, in particular for Magnusiomyces capitatus, Trichosporon asahii, and Rhodotorula mucilaginosa (with values ≥2 mg/L in most of isolates). In addition, T. asahii also showed increased MIC values to amphotericin B (AmB) (1 mg/l by CLSI and 2 mg/l by EUCAST).
Underlying conditions
Host characteristics and predisposing factors in both study groups (rare yeasts BSI and Candida BSI) are shown in Table 4 . Compared to those with candidemia, patients diagnosed with BSI due to rare yeasts had lower Charlson comorbidity index scores and were more likely to have hematological malignancy and chronic obstructive pulmonary disease (COPD) as underlying conditions and to have received immunosuppressive therapy within the preceding month. The prevalence of neutropenia was also significantly higher in the former group. Although not reaching statistical significance, there was a trend for a higher prevalence of previous echinocandin exposure in the rare yeast BSI group (14.3% [2/14] versus 4.9% [37/748] ; P-value = .158). We observed two episodes of breakthrough fungemia due to rare yeasts (M. capitatus in both cases), with no significant differences in the rate of this condition compared to the Candida BSI group.
Clinical presentation, therapy, and outcome
There were no significant differences between both groups in the source of infection, nor in the markers of hemodynamic instability or severity of illness (Table 5) . However, we found a clear trend suggesting a higher proportion of catheter-related episodes in the rare yeasts BSI group compared to the Candida BSI group (57.1% [8/14] 
Discussion
The present study provides a contemporary insight into the epidemiology and clinical and microbiologic profiles of BSI due to non-Candida, non-Cryptococcus yeasts. Notwithstanding the rarity of this condition and its heterogeneity, some common features emerge. Compared to patients with candidemia, those with BSI due to rare yeasts were more likely to have some type of immune impairment (immunosuppressive therapy or neutropenia), underlying COPD and a catheter-related source. MIC values to all echinocandins were generally high. Accordingly, the prior exposure to these antifungal agents was meaningful (14.3%), suggesting a pathogenic role for selective antifungal pressure. Finally, the odds of clinical failure were not apparently increased in this form of invasive fungal disease compared to candidemia.
The definition used for fungemia due to "rare yeasts" varies across studies, 4 and Pichia 6 as the most frequent genera. In addition to potential geographical determinants of species distribution, these discrepancies likely reflect differences among studies in host's predisposing conditions and previous use of antifungals.
5,6
The absence of species-specific CBPs for interpreting antifungal susceptibility test results poses an additional Table 2 . Demographics, clinical and microbiological features, treatment and outcome in episodes of BSI due to rare yeasts. Antifungal susceptibility testing according to the CLSI procedure was performed in only one isolate. challenge in treating BSI due to rare yeasts. 26, 27 In addition, we found some discrepancies in the MIC values obtained according to EUCAST or CLSI guidelines (particularly for triazoles), although direct comparison of these results should be made with caution due to the existence of technical differences between both methods, the poor growth exhibited by most strains, and the fact that both procedures were not run in parallel at the same institution. 21 Not surprisingly, the MIC values observed for echinocandins by either method were particularly high among The recent ESCMID/ECMM guidelines recommend the use of expanded-spectrum triazoles as first-line therapy for invasive trichosporonosis. 4 A recent review of 185 cases reported in the literature found that a significantly higher proportion of patients receiving voriconazole had a favorable outcome compared to other antifungal therapies. 17 In addition, the susceptibility rate to voriconazole assessed by the CLSI method among 164 T. asahii isolates in the ARTEMIS Study was very high (92.1%). 2 In the present experience, the only patient with BSI due to T. asahii who survived was treated with a voriconazole-containing regimen (case 12 in Table 2 ). On the other hand, resistance to AmB in T. asahii is relatively common, 29, 30 as exemplified by the fact that our two isolates exhibited MIC values of 2 mg/l by the EUCAST. Rhodotorula is a ubiquitous saprophytic fungus that may be recovered from environmental sources, and its pathogenicity has been previously questioned, 43 although recent single-center series and literature reviews reported mortality rates of 10-20%. 16, 44 The species included within this genus must be regarded as intrinsically resistant to echinocandins 45 and show variable resistance rates to fluconazole (50-100%) and voriconazole (22-39%) 2, 5 . Therefore, the ESCMID/ECMM guidelines state that AmB (with or without 5-flucytosine) should be preferred as first-line therapy. 4 Accordingly, the two cases with R. mucilaginosa BSI in our cohort received an AmBcontaining regimen. However, only one of them-an immunocompetent patient with previous abdominal surgery and parenteral nutrition-survived (case 5), emphasizing the impact of host's underlying conditions on the prognosis. The isolation of M. capitatus (Dipodascus capitatus) in clinical samples has been rarely reported. 15, 18, 46 The antifungal susceptibility testing of the isolates collected in our study revealed an overall resistance profile against echinocandins (M. capitatus is considered intrinsically resistant 4 ), fluconazole, and expanded-spectrum triazoles. In that sense, we found MIC values to voriconazole higher than those reported by other authors. 18, 47, 48 All three episodes occurred in patients receiving remission-induction or consolidation therapy for acute leukemia and presented with severe clinical manifestations, including disseminated infection (case 3) or septic shock (case 2). These features are concordant with those previously reported in a multicenter study. 11 In line to previous reports, 49, 50 the only two cases of breakthrough BSI in our study were due to M. capitatus and occurred in patients that were receiving echinocandin (cases 3 and 4). Fungemia due to rare yeasts was associated to case fatality rates as high as 40% in previous studies. 5, 10 Focusing on specific pathogens, a negative outcome was reported in 59% and 71% of patients with BSI or other forms of invasive infection due to Trichosporon spp. and M. capitatus, respectively. 17, 18 The demonstration of similar rates of clinical failure or persistent BSI between both study groups (rare yeasts BSI and Candida BSI) represents to some extent an unexpected finding for which there are various nonexcluding explanations. The improvements achieved during the last years in the therapeutic approach to fungemia and in the overall management of underlying conditions may have exerted a favourable effect on the contemporary outcome of BSI due to rare yeasts as compared to historical cohorts. This impact could have been particularly relevant for low-virulent agents such as Pichia spp. Our study was not restricted to tertiary-care or dedicated cancer centers but rather included 29 hospitals of different size and complexity. Therefore, the prevalence of neutropenia at the onset of BSI was lower than in other studies. 5, 11 In addition, the proportion of catheter-related episodes-in which the prognosis is clearly better than in other sources of BSI-was higher within the cases involving rare yeasts. Since the CANDIPOP Study only spanned a one-year period of surveillance, our research is obviously limited by the small number of episodes analyzed and its intrinsic species heterogeneity, which hamper drawing conclusions on specific pathogens. As mentioned, neither EUCAST nor CLSI have defined CBPs for these yeasts. Therefore, we solely described MIC values distribution across different species. Moreover, these data should be taken with particular caution due to the low number of isolates tested. Finally, the absence of specific diagnostic criteria might question whether some of the cases would actually correspond to episodes of pseudofungemia, although it should be emphasized that all the isolates were deemed significant by the attending clinician and prompted the initiation of antifungal therapy. On the other hand, the design of the CANDIPOP Study offers the advantages of centralized molecular identification and antifungal susceptibility testing. 20, 21 In addition, our population-based approach does not share the limitations of previous retrospective series that were based on single-center experiences spanning large study periods, 5, 10 multicenter studies, 11 or literature reviews. 16, 17, 19 In conclusion, the uncommon implication of rare yeasts other than Candida and Cryptococcus in episodes of BSI, the changing taxonomy, and the relative lack of familiarity of clinicians and microbiologists with these opportunistic pathogens pose therapeutic challenges that might be overcome, at least partially, by the advent of dedicated guidelines. 4 The increasing proportion of immunocompromised hosts heralds an emergence over the next decades of cases of invasive fungal infection due to rare yeasts. As our data suggest, further efforts are still needed to better harmonize antifungal susceptibility testing results between committees and to propose species-specific CBPs that would help to define the best therapeutic approaches.
